

OFFICIAL

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

(MBHB Case No. 03-110)

**RECEIVED  
CENTRAL FAX CENTER****MAY 20 2004**

In the Application of:

Di Salle, et al.

Serial No. 09/926,554

Filed: November 19, 2001

For: **Combined Method of Treatment Comprising An  
Aromatase Inhibitor And a Further Biologically  
Active Compound**

Examiner: Shaojia A. Jiang

Group Art Unit: 1617


Confirmation No. 8709

**FACSIMILE TRANSMITTAL LETTER**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450Attn: Examiner Jiang  
Fax (703) 872-9306No. of Pages: 13  
Including this Transmittal Letter

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:
  - a. Supplemental Information Disclosure Statement
  - b. PTO Form 1449 with copy of cited reference
2. No fees are due at this time.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
4. **CERTIFICATE OF TRANSMISSION UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being facsimile transmitted to the Patent and Trademark Office (Fax No. (703) 746-7240) on this 20th day of May, 2004.

  
Lisa M. W. Hillman  
Reg. No. 43,673McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

OFFICIAL  
PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. MBHB 03-110)RECEIVED  
CENTRAL FAX CENTER

MAY 20 2004

In re Application of: )  
 )  
 Di Salle, et al. ) Examiner: Shaojia A. Jiang  
 )  
 Serial No.: 09/926,554 ) Group Art Unit: 1617  
 )  
 Filed: November 19, 2001 ) Confirmation No. 8709  
 )  
 For: Combined Method of Treatment )  
 Comprising An Aromatase )  
 Inhibitor And a Further )  
 Biologically Active Compound )

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 2231-1450

Dear Madam:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449 and copies<sup>1</sup> of the documents listed thereon. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Article References:

1. Okada, et al., "Studies on Aromatase Inhibitors I. Synthesis and Biological Evaluation of 4-Amino-4H-1,2,4-triazole Derivatives", *Chem Pharm Bulletin (Tokyo)*, October 1996, 44(10), pp.1871-1879.

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: 5/20/04

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone: (312) 913-0001  
Facsimile: (312) 913-0002

Respectfully submitted,

  
Lisa M. W. Hillman  
Registration No. 43,673

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

03-110

Serial No.

09/926,554

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Di Salle, et al.

Filing Date:  
November 19, 2001

Group: 1617

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Translation Yes No

**OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.**

1.	Okada, et al., "Studies on Aromatase Inhibitors I. Synthesis and Biological Evaluation of 4-Amino-4H-1,2,4-triazole Derivatives", <i>Chem Pharm Bulletin (Tokyo)</i> , October 1996, 44(10), pp.1871-1879.
----	--

**Examiner****Date Considered**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.